Messenger RNA in covid-19 vaccines could open doors to cancer treatment
The technology used in some Covid-19 doses could facilitate different vaccines or treatments for certain cancers. These advances need the firm and constant support of […]
cancer
Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning
First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive […]
Bayer receives approval for Nubeqa™ in China for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC)
The Chinese National Medical Products Administration (NMPA) has approved Nubeqa™ (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at […]
Europe’s Beating Cancer Plan: A new EU approach to prevention, treatment and care
Today, on the eve of the World Cancer Day, the European Commission is presenting Europe’s Beating Cancer Plan – a main priority in the area […]
Bayer and Systems Oncology sign exclusive license agreement on innovative breast cancer treatment approach ERSO™
Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for the treatment of metastatic […]
Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary […]
Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response
…. regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer • IMpassion031 data will be discussed with health authorities globally, […]
FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
• Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma • […]
Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer
• ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five years (62.5% with Alecensa), […]
CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours
…..and for people with ROS1-positive, advanced non-small cell lung cancer •Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to […]
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
• Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation […]
FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer
On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or […]